Study of BMS-587101 in Patients With Moderate to Severe Psoriasis
NCT00162253
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
120
Enrollment
INDUSTRY
Sponsor class
Conditions
Psoriasis, Moderate to Severe
Interventions
DRUG:
BMS 587101
Sponsor
Bristol-Myers Squibb